Introduction Copper-Iodine Complex Solution (CICS) is an FDA 510(k) cleared medical device as a wound irrigation system. CICS is indicated in wound management, cleansing, irrigating, moisturizing, and debriding of acute and chronic dermal lesions that are partial or full thickness wounds. This unique complex has the capacity to neutralize a broad number of pathogens such as bacteria, viruses, yeast, and fungi without evoking bacterial resistance1-4. Free Iodine (I2) is a recognized powerful and broad-spectrum antimicrobial with no known resistance by exhibiting multi-mechanisms of action, highlighting: (i) penetration into the cell wall of the microorganism, causing blocking of the hydrogen bonds which results in damage to the phospholipid cell membrane, (ii) and damage and denaturing of the essential proteins, nucleotides, and fatty acids by binding to thiol and amine groups, leading to rapid cell death. Free iodine acts as a preservative agent that helps to remove contamination within the CICS for effective wound cleaning. It is not intended to provide therapeutic benefits. CICS has been proven to be non-cytotoxic, non-pyrogenic, non-irritating, and non-sensitizing to dermal tissue. The purpose of this study is to quantitatively evaluate the effect of Copper-Iodine Complex Solution on bacteria, yeast, fungi, and SARS-CoV-2 virus in an in vitro model. Materials and Methods Trial #1 - demonstrates antimicrobial efficacy testing as a preservative in solution using five common organisms at 14 and 28 days. Trial #2 - addresses time – kill data against 15 clinically relevant pathogens. Trial #3 - addresses persistent antimicrobial efficacy after re-inoculation using 3 different time points. Trial #4 - addresses and validates the efficacy of CICS against SARS-CoV-2. Results The results of all 4 independent in vitro studies will be reviewed in detail. There is significant log reduction of bacteria, yeast, and fungi in all invitro evaluation. This is also evident in a variety of time periods that the organisms are exposed to CICS with the associated log reductions of clinical significance. Long-lasting CICS efficacy against ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter sp) and Candida albicans and Candida tropicalis has been demonstrated up to 3 days The final study shows the results of CICS against SARS-CoV-2 virus. After incubation with undiluted CICS for 10 minutes, viral titers dropped by 2 logs (one tailed t-test p-value = 0.0140). After incubation with undiluted CICS for either 30 minutes or 60 minutes, viral titers dropped below the limit of detection (< 75 TCID50 per ml). Conclusion Copper-Iodine Complex Solution has been shown to create a significant log reduction with kill rate in multiple gram positive and gram-negative bacteria, yeast, and fungi. Additionally, CICS has been shown to be effective against SARS-CoV-2 virus. Further studies are needed to support these findings.